^
    2d
    PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC (clinicaltrials.gov)
    P2, N=94, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr)
    2d
    FOLR1 Mediated by ITCH Promotes Paclitaxel Resistance by Suppressing Pyroptosis in Nasopharyngeal Carcinoma. (PubMed, Arch Pharm (Weinheim))
    Lowering FOLR1 expression suppressed tumor growth and boosted paclitaxel sensitivity in mice. FOLR1 plays a significant role in promoting chemoresistance of NPC cells to paclitaxel through NLRP3 signaling.
    Journal
    |
    FOLR1 ( Folate receptor alpha ) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    FOLR1 expression • FOLR1 overexpression
    |
    paclitaxel
    2d
    Fusobacterium nucleatum manipulates host autophagy to promote its intracellular survival and treatment resistance in nasopharyngeal carcinoma. (PubMed, Mol Cancer)
    Our findings elucidate a key mechanism by which F. nucleatum survives and promotes treatment resistance in NPC, providing a microbiological prognosis indicator for NPC patients.
    Journal
    |
    TRIM28 (Tripartite Motif Containing 28)
    2d
    Yiqi Jiedu Formula inhibits proliferation, invasion and migration of nasopharyngeal carcinoma cells by inhibiting the AKT1/GLUT1 signaling pathway (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)
    YQJDF inhibits proliferation, invasion, and migration of NPC cells by inhibiting the AKT1/GLUT1 signaling pathway.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • XIAP (X-Linked Inhibitor Of Apoptosis) • SLC2A1 (Solute Carrier Family 2 Member 1)
    3d
    Androgen receptor may promote tumor progression via TTF-1/EGFR pathway in metastatic nasopharyngeal carcinoma. (PubMed, Transl Oncol)
    Treatment with enzalutamide, an antiandrogen, substantially inhibited patient-derived xenografts growth and demonstrated additive antitumor effects when combined with chemotherapy in AR-positive models...AR expression correlated with poorer overall survival, with statistical significance noted in the full cohort and particularly in male patients. This study suggests that AR may promote metastatic NPC progression via the TTF-1/EGFR signaling pathway and interact with EBV to influence disease behavior, especially in males.
    Journal
    |
    AR (Androgen receptor) • TNFA (Tumor Necrosis Factor-Alpha) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • NKX2-1 (NK2 Homeobox 1)
    |
    AR positive
    |
    Xtandi (enzalutamide)
    3d
    USP18 orchestrates malignant progression in nasopharyngeal carcinoma through UBR5-driven attenuation of p53 signaling. (PubMed, Int Immunopharmacol)
    This study unveils a previously unrecognized oncogenic mechanism wherein USP18 promotes malignant progression of nasopharyngeal carcinoma via UBR5-dependent suppression of the p53 signaling pathway. These findings highlight USP18 as a promising candidate biomarker and potential therapeutic target in NPC.
    Review • Journal
    |
    USP18 (Ubiquitin Specific Peptidase 18) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5)
    3d
    Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P3, N=412, Not yet recruiting, Sun Yat-sen University
    New P3 trial
    |
    cisplatin • gemcitabine • Focus V (anlotinib) • Andewei (benmelstobart)
    4d
    MRG003 Combined With Immunotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, West China Hospital
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    6d
    Study on the Efficacy and Safety of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Xerostomia after Radiotherapy for Nasopharyngeal Carcinoma (ChiCTR2500107372)
    P2, N=10, Not yet recruiting, Fujian Medical University Union Hospital; Fujian Medical University Union Hospital | Initiation date: Aug 2025 --> Jan 2026
    Trial initiation date
    6d
    A cohort study of antibody-nucleic acid two-step method compared with plasma EBVDNA for nasopharyngeal carcinoma (NPC) screening in high-risk areas of China (ChiCTR2600117497)
    P=N/A, N=0, Not yet recruiting, Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University
    New trial
    6d
    Construction and application of an adaptive radiotherapy triggering timing prediction model for nasopharyngeal carcinoma based on artificial intelligence and research on the interpretability of proteomics (ChiCTR2600116728)
    P=N/A, N=100, Not yet recruiting, The First Hospital of China Medical University; The First Hospital of China Medical University
    New trial
    6d
    Long-term significant efficacy of gemcitabine combined with nedaplatin in persistent refractory nasopharyngeal carcinoma involving the cavernous sinus and distant metastasis:a case report (ChiCTR2500115780)
    P=N/A, N=1, Not yet recruiting, The First Affiliated Hospital of Army Medical University; The First Affiliated Hospital of Army Medical University
    New trial
    |
    gemcitabine • Aqupla (nedaplatin)